Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.
Detailed price information for Equillium Inc (EQ-Q) from The Globe and Mail including charting and trades.
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of EQ504 in healthy subjects LA JOLLA, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders,
LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel’s 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. A
LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Co
This is the newest page. Registered accounts read further back.